Related Experiment Video
Updated: Jun 10, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells
Meysam Abbasi1, Afsaneh Lavasanifar, Luc G Berthiaume
1Department of Biomedical Engineering, Faculty of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.
Background:
Among the treatment options that have been developed for cancer, chemotherapy remains 1 of the leading clinical approaches. Chemotherapy can usually control tumor growth at the onset of disease, but its effectiveness becomes limited by the overexpression of transporter proteins responsible for drug efflux, leading to multidrug resistance (MDR). To overcome this obstacle, the authors explored the feasibility of down-regulating the main drug transporter, P-glycoprotein (P-gp), by using nonviral small interfering RNA (siRNA) delivery as means to enhance the accumulation of chemotherapeutic agents in drug-resistant cancer cells.
Methods:
Several cationic carriers capable of siRNA complexation were investigated for P-gp down-regulation in the MDA435/LCC6 cell line and, consequently, increased cellular uptake of the chemotherapeutic agents doxorubicin and paclitaxel.
Results:
Efficient siRNA delivery into tumor cells was demonstrated particularly using a palmitic-acid substituted poly(L-lysine), with no apparent differences in siRNA delivery between the wild type (WT)-expressing and P-gp-expressing phenotype (MDR1) of the cells. Efficient siRNA delivery led to approximately 40% to 50% P-gp suppression (based on the average expression level of the protein), an approximately 3-fold increased DOX uptake, and increased cytotoxicity in MDR1 cells.
Conclusions:
The authors concluded that effective siRNA delivery with nonviral carriers can reduce the level of P-gp on cell surfaces and enhance the efficiency of chemotherapeutic agents in vitro.
Insights
Nonviral small interfering RNA (siRNA) delivery effectively down-regulates P-glycoprotein (P-gp) in multidrug-resistant cancer cells. This approach enhances chemotherapy drug uptake and efficacy in vitro.
Area of Science:
- Biotechnology
- Cancer Research
- Drug Delivery
Background:
- Chemotherapy is a primary cancer treatment, but multidrug resistance (MDR) limits its effectiveness.
- Overexpression of drug efflux transporter proteins, like P-glycoprotein (P-gp), is a key mechanism of MDR.
- Developing strategies to overcome P-gp-mediated MDR is crucial for improving cancer therapy outcomes.
Purpose of the Study:
- To investigate the feasibility of using nonviral small interfering RNA (siRNA) delivery to down-regulate P-gp.
- To enhance the accumulation of chemotherapeutic agents in drug-resistant cancer cells.
Main Methods:
- Evaluation of various cationic carriers for siRNA complexation and delivery.
- Assessment of P-gp down-regulation in MDA435/LCC6 cell lines (wild type and MDR1).
- Quantification of cellular uptake of doxorubicin and paclitaxel.
Main Results:
- Palmitic-acid substituted poly(L-lysine) demonstrated efficient siRNA delivery into tumor cells.
- Successful P-gp suppression of 40%-50% was achieved in MDR1 cells.
- A 3-fold increase in doxorubicin uptake and enhanced cytotoxicity were observed in MDR1 cells.
Conclusions:
- Nonviral siRNA delivery is an effective strategy for reducing P-gp expression on cancer cell surfaces.
- This method can significantly enhance the efficacy of chemotherapeutic agents in vitro.
- siRNA delivery offers a promising approach to combatting P-gp-mediated multidrug resistance in cancer.
More Related Videos
08:31Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...